Literature DB >> 15865885

Optimal role of temozolomide in the treatment of malignant gliomas.

Roger Stupp1, Martin J van den Bent, Monika E Hegi.   

Abstract

Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma. Its role in the treatment of recurrent disease has been confirmed, and more importantly, alternative treatment schedules and combination regimens have been developed. A recent phase III trial has demonstrated a survival advantage for concomitant TMZ administration with radiotherapy in patients with newly diagnosed glioblastoma. Molecular studies suggest a strong predictive role of the DNA repair enzyme O6-methyl-guanine-DNA-methyl-transferase (MGMT) and outcome of TMZ-based chemotherapy. This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15865885     DOI： 10.1007/s11910-005-0047-7

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  59 in total

Review 1.  Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.

Authors:  J A Kovacs; H Masur
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

2.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Authors:  M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

3.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.

Authors:  Raja B Khan; Jeffrey J Raizer; Mark G Malkin; Kimberley A Bazylewicz; Lauren E Abrey
Journal:  Neuro Oncol       Date:  2002-01       Impact factor: 12.300

4.  First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.

Authors:  Alba A Brandes; Umberto Basso; Michele Reni; Francesca Vastola; Alicia Tosoni; Giovanna Cavallo; Luciano Scopece; Andres J Ferreri; Maria G Panucci; Silvio Monfardini; Mario Ermani
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

5.  Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.

Authors:  Jeffrey J Raizer; Mark G Malkin; Martin Kleber; Lauren E Abrey
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

6.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

7.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Authors:  H S Friedman; R E McLendon; T Kerby; M Dugan; S H Bigner; A J Henry; D M Ashley; J Krischer; S Lovell; K Rasheed; F Marchev; A J Seman; I Cokgor; J Rich; E Stewart; O M Colvin; J M Provenzale; D D Bigner; M M Haglund; A H Friedman; P L Modrich
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

8.  A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.

Authors:  Mark R Gilbert; Henry S Friedman; John F Kuttesch; Michael D Prados; Jeffrey J Olson; Gregory H Reaman; Sara L Zaknoen
Journal:  Neuro Oncol       Date:  2002-10       Impact factor: 12.300

9.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Authors:  A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

10.  Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors.

Authors:  Anuj K Mahindra; Stuart A Grossman
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.506
View more
  67 in total

1.  The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.

Authors:  Haihao Zhu; Steve Woolfenden; Roderick T Bronson; Zahara M Jaffer; Sofia Barluenga; Nicolas Winssinger; Allan E Rubenstein; Ruihong Chen; Al Charest
Journal:  Mol Cancer Ther       Date:  2010-07-19       Impact factor: 6.261

2.  Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.

Authors:  Sara Nava; Daniela Lisini; Simona Pogliani; Marta Dossena; Anna Bersano; Serena Pellegatta; Eugenio Parati; Gaetano Finocchiaro; Simona Frigerio
Journal:  Stem Cells Transl Med       Date:  2015-08-13       Impact factor: 6.940

Review 3.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

4.  Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.

Authors:  Claudia R Oliva; Susan E Nozell; Anne Diers; Samuel G McClugage; Jann N Sarkaria; James M Markert; Victor M Darley-Usmar; Shannon M Bailey; G Yancey Gillespie; Aimee Landar; Corinne E Griguer
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

5.  Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.

Authors:  Manish K Aghi; E Antonio Chiocca
Journal:  Mol Ther       Date:  2009-01       Impact factor: 11.454

6.  Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.

Authors:  Silke Glage; Andrew L Lewis; Patricia Mertens; Steffen Baltes; Peter Geigle; Thomas Brinker
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

7.  Improved survival time trends for glioblastoma using the SEER 17 population-based registries.

Authors:  Matthew Koshy; John L Villano; Therese A Dolecek; Andrew Howard; Usama Mahmood; Steven J Chmura; Ralph R Weichselbaum; Bridget J McCarthy
Journal:  J Neurooncol       Date:  2011-10-09       Impact factor: 4.130

Review 8.  Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Authors:  Gulten Tuncel; Rasime Kalkan
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

9.  Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Authors:  Tommy Alain; XueQing Lun; Yvan Martineau; Polen Sean; Bali Pulendran; Emmanuel Petroulakis; Franz J Zemp; Chantal G Lemay; Dominic Roy; John C Bell; George Thomas; Sara C Kozma; Peter A Forsyth; Mauro Costa-Mattioli; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  Hybrid mathematical model of glioma progression.

Authors:  M L Tanaka; W Debinski; I K Puri
Journal:  Cell Prolif       Date:  2009-07-17       Impact factor: 6.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.